United States · Business magazines · Markets Insider (Business Insider)

Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform

Published by Markets Insider (Business Insider) · United States 4 h ago

NANJING, China, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (âLeads Biolabsâ, Stock Code: 9887.HK) today announced updated firstâinâhuman clinical…

Read the full article on Markets Insider (Business Insider) Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (markets.businessinsider.com)

Also worth reading

Inc.

Your Lazy Weekend Might Be the Reason You’re So Tired on Monday

Fortune

‘Everyone is hedging.’ As the U.S. and China divide the world into rival AI blocs, that lends power to ‘swing countries’ in between

Kiplinger

Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform

Share

Also worth reading

Your Lazy Weekend Might Be the Reason You’re So Tired on Monday

‘Everyone is hedging.’ As the U.S. and China divide the world into rival AI blocs, that lends power to ‘swing countries’ in between

Can a Roth Conversion Wait if You're 5-10 Years From Retiring?

Look up tonight: October’s full moon is for hunters

When A Health Challenge Changes How You Think About Work

How the conservative Supreme Court has rewritten the rules for the midterms